Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIMULUS-MDS2: MBG453 plus azacitidine vs placebo plus azacitidine in higher-risk MDS or CMML-2
jRCT2080225135Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) comparing MBG453 plus azacitidine with Placebo plus azacitidine (2 arms). Primary endpoint: Overall survival. Started Mar 2020; status: completed.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on jRCT2080225135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225135.